En Bloc vs Standard Resection Found to Lower Bladder Cancer Recurrence Rate
Investigators observe no significant difference between the surgical approaches in 1-year progression rates.
American Urological Association Annual Meeting
The EMBARK Trial: An Interview With Neal D. Shore, MD
The phase 3 EMBARK trial involved more than 200 global sites and had 8 years of follow-up.
BCG Response in Bladder Cancer Cases Linked to Tumor Microbiome
New findings suggest that Lactobacillus bacteria in the tumors of patients with non-muscle invasive bladder cancer increase uptake of bacillus Calmette-Guérin.
TURP Still Most Common BPH Procedure Despite Growing Use of Other Therapies
Some studies show that use of transurethral resection of the prostate, long the gold standard for managing enlarged prostates, is in decline, but it still remains the most popular choice among surgeons amid a wide range of options.
AUA, SUO Issue New Guideline on Nonmetastatic UTUC
The new guideline aims to limit toxicity and improve cancer control and survival in patients with UTUC.
Robotic-Assisted vs Open Kidney Transplantation: The Pros and Cons
The debate was highlighted at the American Urological Association’s 2023 Annual Scientific Meeting.
Enzalutamide Ups Metastasis-Free Survival in nmHSPC
Investigators report results from the phase 3 randomized EMBARK trial.
Biochemical Recurrence Risk Differs by Prostate Cancer Zone
Finding is based on a meta-analysis of 14 high-quality studies involving 19,365 patients.
Intramuscular Testosterone Therapy Tied With Rise in Hematocrit
The risk of hematocrit elevation may depend on testosterone therapy’s route of administration, according to investigators.
UTUC Recurrence After Endoscopic Treatment ID’d as Only Mortality Predictor
Findings are based on a study of 215 patients who underwent 392 endoscopic procedures for upper tract urothelial carcinoma.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in AUA 2023 Annual Meeting
Loading... 
Loading...